Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Zargis Medical Corp. Begins Sale of Cardioscan Software, Addressing Cardiac Concerns

Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE:SI), a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), develops diagnostic decision support products and services for healthcare professionals. The company today announced that it has begun selling its Zargis Cardioscan heart sound analysis software, as well as 3M Health Care’s (NYSE: MMM) recently launched Bluetooth-enabled 3M Littmann Electronic Stethoscope Model 3200.

The introduction of the products into the marketplace is part of Zargis’ existing multi-year global marketing deal with 3M, which equips Zargis with extended marketing and promotional opportunities, as well as worldwide distribution rights of its products through 3M’s Littmann brand.

Zargis’ Cardioscan software provides support to physicians, analyzing and interpreting cardiac sounds, which gives them an upper hand in dealing with possible heart disease. Cardioscan is wirelessly connected to 3M’s Littmann Electronic Stethoscope Model 3200, which allows users to easily share and compare heart sounds recordings and related comments over the Internet.

“The ability to record and automatically analyze heart sounds can help improve a clinician’s confidence, document complex auscultations, and may keep some patients from going through additional, unnecessary testing,” Joseph Tartaglia, MD, a practicing cardiologist in White Plains, NY, and clinical assistant professor of medicine at New York Medical College in Valhalla, NY, stated in the press release.

Today’s announcement comes in the middle of the U.S. healthcare controversy and the public call for improved and accessible healthcare.

“At a time when our nation is focused on leveraging technology to improve healthcare efficiency, these devices represents breakthroughs in auscultation that have the potential to reduce unnecessary referrals, and help clinicians detect pathologic heart murmurs earlier in the treatment cycle,” John Kallassy, CEO of Zargis stated. “We believe that the use of our software could enhance the physician experience during every patient exam where a stethoscope is used.”

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *